Hints and tips:
Related Special Reports
...and healthcare professionals is not a new concept for Haleon, it is becoming only more critical as we look to help make everyday health more accessible and achievable for everyone”....
...Haleon, the consumer products business spun out of UK pharma group GSK, is clearing its cache. It will offload ChapStick to private equity for $430mn....
...This follows GSK’s spin-off of its consumer health division Haleon, and the strong performance of its vaccines unit, including Arexvy, a new vaccine for respiratory syncytial virus that reached blockbuster...
...Haleon has hired Dawn Allen as chief financial officer beginning in October. She previously worked for Tate & Lyle and Mars....
...“The people that stayed with GSK after the separation from Haleon were effectively employees of a new company, with a new purpose, strategy and culture,” he notes....
...Haleon was a joint venture between GSK and Pfizer that included consumer brands acquired from Novartis....
...Rogers, the Haleon marketing chief, says: “The injection of originality and creativity is really critical. When you’re seeing 40,000 pieces of content in a day, you need to stand out....
...Investors were dismayed by the failed £50bn bid for GSK’s consumer healthcare arm, now Haleon, early last year....
...GSK reported continuing earnings per share of 40.1p, adjusted for the spin-off of Haleon, a rise of more than 100 per cent year on year, and above the average analyst estimate of 34.7p....
...A handful of the world’s biggest pharmaceutical companies, including GSK, Haleon, Sanofi and Pfizer, had more than £30bn wiped off their market value in August 2022 as investors became increasingly alarmed...
...Investors had wiped a combined £30bn from the valuations of GSK, its consumer spin-off Haleon, Sanofi and Pfizer over two days in August last year over fears about lawsuits related to Zantac, and the size...
...Haleon, GSK’s consumer health division which was spun out last year and which manufactures products such as Panadol painkillers and Sensodyne toothpaste, also announced it would shift to a third-party distribution...
...Investors are now focused on how GSK spends its Haleon dividend....
...The legal team worked across operations, branding and regulatory approvals, to ensure that GSK and Haleon could function as separate entities from day one....
...It has only been a year since it sold off its consumer healthcare business, now trading as Haleon, in an effort to focus more on vaccines and prescription medications....
...Leverage has fallen and cash is still plentiful thanks to the Haleon spin-off. Judgment on that deal awaits more evidence on how well the proceeds have been used....
...Investors wiped more than a combined £30bn from the valuations of GSK, Haleon, Sanofi and Pfizer last August, amid concerns about a huge legal bill from a barrage of legal cases....
...“We do not agree with Haleon’s position....
...UK pharma group GSK has spun off Haleon on the basis that there is limited overlap between selling Advil and developing HIV vaccines....
...Peltz had built a stake in the early months of 2022, after Unilever’s share price slumped following its botched attempt to buy GlaxoSmithKline’s consumer healthcare arm, later spun out as Haleon....
...The largest maker of cold and flu medicines globally is US-based Johnson & Johnson, followed by London-listed Haleon and Reckitt Benckiser, according to Euromonitor....
...That has made for what UK consumer health group Haleon — spun out of GSK last week — cheerfully describes as a “strong” cold and flu season....
...Shareholders received one Haleon share for each GSK share they own....
...The group’s market capitalisation was around £80bn in February 2022 before the Haleon demerger was announced....
...A failed £50bn bid last year for GSK’s consumer health business, later spun out to become London-listed Haleon, was scorned by investors as strategically dubious....
International Edition